Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
暂无分享,去创建一个
J. Bendell | I. Braña | L. Siu | C. Massacesi | L. Trandafir | E. Tomaso | C. Sarr | M. D. Jonge | F. Eskens | D. Mills | J. Rodón | N. Homji